Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,904 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
Interventions
NT-175
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Conditions
Multiple System Atrophy
Interventions
Placebo, TAK-341
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Farmington Hills, Michigan • Rochester, Minnesota • New York, New York + 4 more
Conditions
Skin Cancer
Interventions
Iressa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Rhinitis, Allergic, Perennial, Hay Fever
Interventions
Ciclesonide nasal, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940

NCT00659490
Conditions
Pain
Interventions
AZD1940, Naproxen, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Semaglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
64
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 57 more
Conditions
Cardiovascular Disease
Interventions
ticagrelor, prasugrel, Placebo
Drug
Lead sponsor
Yochai Birnbaum
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Houston, Texas
Conditions
Hypercholesterolaemia
Interventions
laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3, laroprovstat/rosuvastatin 4, Placebo to match laroprovstat/rosuvastatin 1,2,3, Placebo to match laroprovstat/rosuvastatin 4, Rosuvastatin 1, Rosuvastatin 2, Rosuvastatin 3, Rosuvastatin 4, Placebo to match Rosuvastatin
Combination Product · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Sun City West, Arizona • Gardena, California • Lomita, California + 22 more
Conditions
Relative Bioavailability
Interventions
BDA MDI 160/180 mcg, Pulmicort Flexhaler 180 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma, Germinomatous Germ Cell Tumor, Dysgerminoma, Pineal Germ Cell Tumor
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Placebo to formoterol fumarate, Once-daily formoterol fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Tucson, Arizona • Fullerton, California • Lakewood, California + 36 more
Conditions
Carcinoma, Non-Small-Cell Lung Carcinoma, Head and Neck Neoplasms
Interventions
AZD2171
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Interventions
Ramucirumab, MEDI4736
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Santa Monica, California • Baltimore, Maryland • St Louis, Missouri + 4 more
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, MEDI-570 0.03 MG, MEDI-570 0.1 MG, MEDI-570 0.3 MG, MEDI-570 1 MG
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Long Beach, California • San Leandro, California • Fort Lauderdale, Florida + 6 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide once weekly suspension, Exenatide twice daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
58
States / cities
Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Conditions
Generalized Anxiety Disorder
Interventions
Quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Springdale, Arizona • Little Rock, Arkansas • Encino, California + 55 more
Conditions
Severe Eosinophilic Asthma, Nasal Polyps
Interventions
FASENRA(benralizumab)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Conditions
Malignant Neoplasms of Female Genital Organs
Interventions
Fulvestrant, Abemaciclib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anxiety Disorders
Interventions
AZD7325, Lorazepam, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Mesa, Arizona • Little Rock, Arkansas • Carson, California + 48 more
Terminated Phase 2 Interventional Results available

Phase II Study of ZD6474 in Advanced NSCLC

NCT00290537
Conditions
Lung Cancer
Interventions
ZD6474, Carboplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas